Meeting
2014 ASCO Annual Meeting
tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).
Authors
Denise A. Yardley
Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN
Denise A. Yardley , Adam Brufsky , Robert E. Coleman , Pier Franco Conte , Javier Cortes , Stefan Glück , Jean-Marc A. Nabholtz , Joyce O'Shaughnessy , Li Li , Debora Barton , Robert M. Beck , Nadia Harbeck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
NCT01881230
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS1146)
DOI
10.1200/jco.2014.32.15_suppl.tps1146
Abstract #
TPS1146
Poster Bd #
233A
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).
First Author: Denise A. Yardley
Poster
2023 ASCO Annual Meeting
FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer.
First Author: Shao Zhimin
Poster
2018 ASCO Annual Meeting
An open label, single arm, prospective phase II study to evaluate the efficacy and safety of bevacizumab with gemcitabine and carboplatin as first-line treatment for metastatic triple negative breast cancer patients.
First Author: Sudeep Gupta
Poster
2023 ASCO Annual Meeting
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).
First Author: Benedikt Westphalen